[{"address1": "Clarendon House", "address2": "2 Church Street", "city": "Hamilton", "zip": "HM 11", "country": "Bermuda", "website": "https://www.kiniksa.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.", "fullTimeEmployees": 297, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sanj K. Patel", "age": 54, "title": "CEO & Chairman of the Board", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 1444526, "exercisedValue": 0, "unexercisedValue": 9860411}, {"maxAge": 1, "name": "Mr. Eben  Tessari", "age": 41, "title": "Senior VP & COO", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": 643751, "exercisedValue": 0, "unexercisedValue": 1625321}, {"maxAge": 1, "name": "Dr. John F. Paolini", "age": 58, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 753702, "exercisedValue": 0, "unexercisedValue": 3678576}, {"maxAge": 1, "name": "Mr. Mark  Ragosa C.F.A.", "age": 49, "title": "Senior VP & CFO", "yearBorn": 1974, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael R. Megna CPA", "age": 52, "title": "Chief Accounting Officer & Group VP of Finance", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mei  Jang", "title": "Senior VP of Technical Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Rachel  Frank", "title": "Associate Director of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chad  Morin", "title": "Senior VP & Chief Compliance Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Madelyn Demsky Zeylikman", "age": 49, "title": "SVP, General Counsel & Secretary", "yearBorn": 1974, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Manno", "title": "Senior VP & Chief Human Resources Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 16.91, "open": 17.1, "dayLow": 16.87, "dayHigh": 17.43, "regularMarketPreviousClose": 16.91, "regularMarketOpen": 17.1, "regularMarketDayLow": 16.87, "regularMarketDayHigh": 17.43, "beta": 0.302, "trailingPE": 85.475, "forwardPE": 341.9, "volume": 352915, "regularMarketVolume": 352915, "averageVolume": 362367, "averageVolume10days": 344520, "averageDailyVolume10Day": 344520, "bid": 17.05, "ask": 17.13, "bidSize": 100, "askSize": 100, "marketCap": 1207163392, "fiftyTwoWeekLow": 10.645, "fiftyTwoWeekHigh": 22.09, "priceToSalesTrailing12Months": 4.4666905, "fiftyDayAverage": 19.4259, "twoHundredDayAverage": 17.64875, "currency": "USD", "enterpriseValue": 1013050816, "profitMargins": 0.05211, "floatShares": 930706, "sharesOutstanding": 39980300, "sharesShort": 3209806, "sharesShortPriorMonth": 2779945, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.045500003, "heldPercentInsiders": 0.03963, "heldPercentInstitutions": 0.90342003, "shortRatio": 7.27, "shortPercentOfFloat": 0.087799996, "bookValue": 6.228, "priceToBook": 2.7448618, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": 4.657, "netIncomeToCommon": 14084000, "trailingEps": 0.2, "forwardEps": 0.05, "pegRatio": 1.01, "enterpriseToRevenue": 3.748, "enterpriseToEbitda": -44.325, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "KNSA", "underlyingSymbol": "KNSA", "shortName": "Kiniksa Pharmaceuticals, Ltd.", "longName": "Kiniksa Pharmaceuticals, Ltd.", "firstTradeDateEpochUtc": 1527255000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7ea20e71-749b-31b8-994b-79f75933ead7", "gmtOffSetMilliseconds": -14400000, "currentPrice": 17.095, "targetHighPrice": 32.0, "targetLowPrice": 25.0, "targetMeanPrice": 28.75, "targetMedianPrice": 29.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 206371008, "totalCashPerShare": 2.922, "ebitda": -22855000, "totalDebt": 12258000, "quickRatio": 3.575, "currentRatio": 4.34, "totalRevenue": 270259008, "debtToEquity": 2.793, "revenuePerShare": 3.858, "returnOnAssets": -0.03194, "returnOnEquity": 0.03373, "freeCashflow": 13786500, "operatingCashflow": 13301000, "earningsGrowth": 5.5, "revenueGrowth": 0.348, "grossMargins": 0.66723996, "ebitdaMargins": -0.08457, "operatingMargins": 0.00097000005, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-23"}]